China, the second largest pharmaceutical market in the world, is a pharmerging giant, with around 6,500 pharmaceutical manufacturing companies producing 1,500 types of APIs. Apart having some of the largest patented API producers worldwide, there are 16,000 medical device and equipment manufacturing companies, which produce about 3,000 kinds of products such as MRI and CT.
Pharma R&D and production in China has grown both in terms of volume production and evolved its quality and regulatory environment rapidly in the last few years. At the core of the country’s success has been a diversity of companies, a strident approach to work around the clock and the spirit of innovation to advance production and lower costs.
In the next three to five years, China’s healthcare market will grow at a rate of around 10 per cent per year. The country’s 13th Five-year Plan is focused on advancing technology and upgrading product quality and policy to encourage development of international trade and investment. There is also an increasing importance in the biopharmaceutical industry and biosimilars.
The government has also taken many steps to change the regulatory environment in order to boost the industry, most notably, the launch of the Market Authorization Holder (MAH) pilot scheme and proposed easing of foreign drug registration regulation. The latter will speed-up drug approvals, as foreign drug-makers will be able to file a new drug approval using data from international, multicentre trials – when in the past, a specific Chinese trial would often also be required.
Similarly, the MAH is already helping to drive market innovation and expediting time to the market for many international companies, not to mention facilitating rapid growth in China based CDMOs. It allows license holders of a drug to sell in China using a contract manufacturer, instead of being required to manufacture the drug themselves. So, it’s a hugely dynamic time for international companies operating or looking to expand here.
The detailed pilot plan for the MAH system is a revolutionary process in the development of biopharmaceutical innovation in China. The new system allows the license holders of a drug to sell in China using a contract manufacturer, instead of manufacturing the drug themselves. This makes it easier for the growing number of Chinese biotech’s to progress their own products through clinical development; they are no longer required to invest in their own manufacturing facilities. However, it also means that foreign drug license holders can now use contract facilities in China, providing much easier access to the market.
CPhI China 2017
These favourable macro trends are reflected at CPhI China 2017 where more than 2,800 exhibitors will greet over 40,000 professional visitors from more than 120 countries at this high value-added sharing platform to create unlimited business opportunities. In the last year there has been an impressive surge in international attendees as multinational companies increasingly look for local manufacturers and partners.
CPhI & P-MEC China will be returning for its 17th edition to the Shanghai New International Expo Centre (SNIEC) in Shanghai, China from June 20 to 22, 2017, gathering companies from across the world, providing solutions for the needs of the entire pharmaceutical supply chain, including pharmaceutical ingredients, growing biopharmaceutical industry, laboratory equipment, pharma packaging, machinery, logistics, environmental and clean room solutions.
CPhI China is the most comprehensive pure pharma focused event for domestic and international pharmaceutical companies in Asia. Attendees will get an opportunity to meet, network, do business, share ideas and shape the future of the Chinese pharmaceutical industry.
The event is once again co-located with ICSE, InnoPack, BioPh, NEX, LABWorld, EP & Clean Room Technology, p-Logi, Health Ingredients China, Fi (Food Ingredients) Asia – China, and FDF (Finished Dosage Formulation) China 2017. The event will bring together attendees from over 120 countries of which 20 per cent are international, from countries including Germany, USA, Netherlands, Italy, India, Korea and Japan.
The event will be providing solutions covering the needs of the entire pharmaceutical supply chain, including pharmaceutical ingredients, growing biopharmaceutical industry, laboratory equipment, pharma packaging, machinery, logistics, environmental and clean room solutions.
The exhibition serves not only as trading & networking, but also learning platform providing with access to the latest market updates, regulatory news and more Alongside the show, the very first edition of CPhI China Pharma Week will take place from June 19 – 23, 2017, covering six streams of the pharmaceutical industry, including leadership, business, networking, recognition, knowledge and innovation.
The CPhI China Pharma Week 2017 represents a celebration of the pharmaceutical industry and will offer full range of opportunities to understand and trade with one of the biggest Pharma market, China. The five-day China Pharma Week will show the present and set the scene for the future of the Chinese pharmaceutical industry in multiple ways.
Conferences and forums like the 8th China-World CEO Summit, CPhI & ICSE China Innovation and Development Forum, 6th P-MEC Summit and 2017 CPhI & P-MEC Green Pharma Summit will gather global leaders of pharmaceutical industry to have conversation about new development trends of pharmaceutical economy and technology.
InnoPack, EP & Clean Tech, NEX Innovative Product Show and Discovery Tour will be showcasing Chinese and overseas quality innovative products and advanced technology, to encourage the pharmaceutical technological innovation of China.
The co-located events ICSE
With its cost advantage and increasing R&D capability, China has gradually become a priority sourcing hub for multinational pharmaceutical companies and biotech companies. The establishment of new policies has also created tremendous opportunities for the CRO & CMO industry in China.
Moreover, the development of innovative new drugs has become the focus of the pharmaceutical companies nowadays. With the gradual release of China's R&D demand, the pharmaceutical industry will face intensify reform.
In the next few years, China's pharmaceutical R&D outsourcing industry will usher in new development opportunities and become an important part of the pharmaceutical R&D industry chain. It is expected that by 2018, China's pharmaceutical R&D outsourcing market size will exceed 60 billion RMB.
BioPh
First launched in 2012, BioPh China has become one of Asia's top exhibitions dedicated to the fields of biotech, clinical trials, gene engineering, antibody engineering, cell cultures, bio-instruments and related products and technologies. The show has established itself as an industry-leading international platform in Asia for pharmaceutical/biotech companies, research institutes and all other industry stakeholders to meet, network and discuss the latest industry trends, partnership models and investment opportunities in Asia and across the globe.
NEX
As “Healthy China 2020” is being incorporated into China’s national strategy, the consumption demand on health products continues to grow. Natural extract, as an “aggregate” belonging to the pharmaceutical, fine chemical and agriculture industry, plays an important role in the larger health industry chain. The application field of natural extracts has been extended to pharmaceutical ingredients, neutraceutical/functional products, food additives, cosmetics, feed additives and more.
Hi China
Hi China will bring an extensive offering in health ingredients which can be used in health food and beverage, functional food, dietary supplements and nutraceuticals. This exhibition will gather over 23,000 leading local and international buyers, looking to research and discover new ideas and solutions. Hi China 2017 is a key food and beverage market for businesses globally and Health ingredients China, together with it's co-located events deliver the entire value chain for the health ingredients, food ingredients, nutraceuticals and functional food industries, all under one roof.
FDF
As an important part of CPhI China, the dosage zone has a brand new launch for 2017 – dedicated solely to Finished Dosage Formulation (FDF). FDF China will bring every aspect of the finished dosage supply chain together in one global location, from Big Pharma to in/out-licensing specialists, end product distributors and end-user agents. According to some estimates, China's finished dosage export growth accelerated in the first three quarters of 2016.